Newsletter | August 21, 2026

08.21.26 -- From Cell Therapy To Clinical Trials: Insights Driving Biotech Forward

FEATURED ARTICLE

Cell Therapy Advances And Biotech Leadership With Nkarta's Paul Hastings

On this week's episode of the Business of Biotech, Paul Hastings, Founding CEO and Board Member at Nkarta, an allogeneic cell therapy developer, talks about building off-the-shelf CAR NK cell therapies for autoimmune disease.

INDUSTRY INSIGHTS

The Triple Effect Of Community-Based Clinical Trials

Taking trials into local communities improves access, boosts enrollment, reduces dropouts, and yields more representative data, speeding timelines and strengthening study quality.

Is An Overlooked Literacy Gap Stalling Clinical Trial Enrollment?

Here, we examine the critical disconnect in a patient's understanding and how purpose-built AI platforms can translate complex medical language into plain, accessible communication.

Opus Genetics Gains Momentum In Inherited Retinal Disease Treatments

See how research is opening new possibilities for rare inherited retinal diseases, with early clinical findings showing restored visual function, encouraging tolerability, and regulatory momentum.

A Guide To Scale-Up And Purification For Small, Large Molecules

Advance your separation and purification strategies by leveraging modern industrial chromatography approaches that scale reliably from lab to production across small-molecule and biologics manufacturing.

Optimizing Charge And N-glycan Profiles For CHO-Derived Fusion Proteins

Discover how structured design-of-experiment approaches can optimize charge variants and glycosylation to enhance biologics quality and therapeutic performance.

Connect With Life Science Leader: